Immunic, Inc. to Participate in Investor Conferences in September
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Continuation of the strong sales momentum initiated in H1 2021 EKKO pilot approved by a European leader in automotive assistance services Solid revenue visibility: FY 2022 guidance confirmed with
NEW YORK, Aug. 16, 2022 /PRNewswire/ -- Immunic, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic... | August 16, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Issuer: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference 02.08.2022 / 12:30 The issuer is solely responsible